ADAM17 and lung carcinoma: Using the novel ADAM17-directed inhibitory antibody MEDI3622, we have now demonstrated a strong antiangiogenic effect in response to the combined treatment modality of radiotherapy with MEDI3622 in a subcutaneous and an orthotopic lung carcinoma model, which was corroborated with the angiogenesis-oriented CAM assay.